Cited 0 times in Scipus Cited Count

Efficacy and Safety of Nebivolol and Rosuvastatin Combination Treatment in Patients with Concomitant Hypertension and Hyperlipidemia

DC Field Value Language
dc.contributor.authorRhee, MY-
dc.contributor.authorKim, CH-
dc.contributor.authorAhn, Y-
dc.contributor.authorShin, JH-
dc.contributor.authorHan, SH-
dc.contributor.authorKang, HJ-
dc.contributor.authorHong, SJ-
dc.contributor.authorKim, HY-
dc.date.accessioned2022-11-29T01:43:45Z-
dc.date.available2022-11-29T01:43:45Z-
dc.date.issued2020-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/23070-
dc.description.abstractPURPOSE: We evaluated the efficacy and safety of nebivolol and rosuvastatin combination treatment in patients with hypertension and hyperlipidemia.

PATIENTS AND METHODS: Eligible patients, after more than 4 weeks of therapeutic lifestyle change, were randomly assigned to three groups: 5 mg nebivolol plus 20 mg rosuvastatin (NEBI/RSV), 20 mg rosuvastatin (RSV), or 5 mg nebivolol (NEBI). Treatments lasted 8 weeks.

RESULTS: Efficacy was analyzed using data from 276 patients. Sitting systolic and diastolic blood pressures differed between the NEBI/RSV and RSV groups (LSmean difference = -5.89 and -5.99 mmHg; 95% confidence interval [CI] = -9.88 to -1.90 mmHg and -8.13 to -3.84 mmHg, respectively). Reductions in the two pressures did not differ between the NEB/RSV and NEB groups. The percent reduction in low-density lipoprotein (LDL) cholesterol differed between the NEBI/RSV and NEBI groups (LSmean difference = -47.76%, 95% CI = -52.69 to -42.84%) but not between the NEBI/RSV and RSV groups. The blood pressure (BP) control rate was higher in the NEBI/RSV group than in the RVS group (51.09% vs 29.67%, p = 0.003). The LDL cholesterol goal achievement rate was higher in the NEBI/RSV group than in the NEBI group (85.87% vs 11.83%, p < 0.001). The incidence of adverse drug reactions in the NEBI/RSV, RSV, and NEBI groups was 8.51%, 7.45%, and 8.60%, respectively (p = 0.950).

CONCLUSION: Nebivolol plus rosuvastatin treatment is effective in reducing BP and LDL cholesterol levels and is safe in patients with hypertension and hypercholesterolemia without the loss of BP or the LDL cholesterol-lowering effect of each drug.

TRIAL REGISTRATION: CRIS registration number KCT0002148.
-
dc.language.isoen-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHDouble-Blind Method-
dc.subject.MESHDrug Therapy, Combination-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHHyperlipidemias-
dc.subject.MESHHypertension-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNebivolol-
dc.subject.MESHRosuvastatin Calcium-
dc.subject.MESHYoung Adult-
dc.titleEfficacy and Safety of Nebivolol and Rosuvastatin Combination Treatment in Patients with Concomitant Hypertension and Hyperlipidemia-
dc.typeArticle-
dc.identifier.pmid33235439-
dc.identifier.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7680129-
dc.subject.keywordhypertension-
dc.subject.keywordhypercholesterolemia-
dc.subject.keywordnebivolol-
dc.subject.keywordrosuvastatin-
dc.contributor.affiliatedAuthorShin, JH-
dc.type.localJournal Papers-
dc.identifier.doi10.2147/DDDT.S280055-
dc.citation.titleDrug design, development and therapy-
dc.citation.volume14-
dc.citation.date2020-
dc.citation.startPage5005-
dc.citation.endPage5017-
dc.identifier.bibliographicCitationDrug design, development and therapy, 14. : 5005-5017, 2020-
dc.identifier.eissn1177-8881-
dc.relation.journalidJ011778881-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Cardiology
Files in This Item:
33235439.pdfDownload

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse